Combination of shikonin with paclitaxel overcomes multidrug resistance in human ovarian carcinoma cells in a P-gp-independent manner through enhanced ROS generation

Paclitaxel is one of the most widely used chemotherapy drugs in the world. In ovarian cancer, a disease that kills the majority of patients with advanced stages, largely because it is detected late, paclitaxel serves as a frontline weapon. Here's the problem: cancer cells learn to neutralize it. They do not become invincible, but instead, they take on an almost mechanical response. They express a protein called P-glycoprotein, or P-gp, which is an efflux transporter that sits in the cell membrane and pumps the drug back out before it can trigger cell death. The chemotherapy arrives, the pump ejects it, and the cell survives. Researchers have spent decades trying to block that pump directly, but it hasn't worked. The side effects and drug interactions have been severe enough to sink most clinical trials. So, Wang and colleagues asked a different question entirely: what if you do not block the pump at all? What if you flood the cell with something the pump cannot handle? The something they chose was shikonin, a naphthoquinone compound isolated from the root of Lithospermum, a plant long used in traditional Chinese medicine. What makes shikonin scientifically interesting is not just its natural origin. It affects cancer cells through an unusual number of pathways at once: the p53 protein, epidermal growth factor receptor signaling, proteasome function, glycolytic metabolism, and, critically, reactive oxygen species, or ROS, which are unstable oxygen molecules that, at high enough concentrations inside a cell, trigger cell death. A compound that attacks through multiple channels simultaneously is harder for a cancer cell to escape. That multi-target profile was the reason Wang and colleagues positioned shikonin as a candidate to combine with paclitaxel against drug-resistant disease. The experimental system they built was clean and well-chosen. They used two human ovarian carcinoma cell lines: A2780, which is sensitive to paclitaxel, and A2780/PTX, its paired derivative that has developed resistance. Cell viability was measured using the Sulforhodamine B assay. The degree of resistance was stark. Paclitaxel at a one hundred nanomolar concentration reduced A2780 cell viability by about sixty-five percent. In A2780/PTX cells, that same concentration produced only seven point eight percent inhibition. The resistant cells were essentially shrugging off a dose that would kill most of their sensitive counterparts. However, when shikonin was combined with paclitaxel, the picture changed dramatically. By using CompuSyn software to calculate combination index values, where a value below one indicates synergy, the team found that the combination was synergistic specifically in the resistant A2780/PTX cells. In the sensitive A2780 line, the interaction was generally additive or even slightly antagonistic. The synergy was targeted exactly where it needed to be. Apoptosis data confirmed the effect. In resistant A2780/PTX cells, shikonin alone and paclitaxel alone each induced only weak or negligible programmed cell death. But the combination pushed apoptosis to thirty point nine percent. The resistant cells were dying in numbers that neither drug could achieve on its own. Then came the twist. Because P-gp overexpression is the textbook mechanism of paclitaxel resistance, the team tested whether the combination was working by suppressing the pump. It was not. Flow cytometry showed that P-gp expression in A2780/PTX cells remained remarkably high. Two separate functional assays—a fluorometric multidrug resistance dye assay and a rhodamine one hundred twenty-three efflux assay—showed that neither shikonin, nor paclitaxel, nor the combination had any meaningful effect on P-gp activity. Verapamil, the positive control drug known to block P-gp, changed the efflux profile, but the shikonin combination did not. The pump was still running, yet the cells were still dying. The resistance was not being reversed by silencing the pump—something else was doing the work. That something else was reactive oxygen species. Wang and colleagues measured intracellular ROS using the dye CM-H2DCFDA and flow cytometry. Shikonin alone and paclitaxel alone each produced only slight, statistically insignificant increases in ROS in both cell lines. However, the combination generated a significant ROS signal in both A2780 and A2780/PTX cells. To test whether that ROS was actually causing the cell death, rather than just accompanying it, the team introduced N-acetyl cysteine, or NAC, a ROS scavenger, at a five millimolar concentration. What happened next is the crux of the paper. In paclitaxel-sensitive A2780 cells, adding NAC before the combination treatment did not rescue the cells. Apoptosis in these cells, which ran at fifty-seven point five percent under the shikonin and paclitaxel combination, was not significantly altered by ROS scavenging. In the resistant A2780/PTX cells, however, the story was completely different. NAC significantly reduced the cytotoxicity, apoptosis, and PARP cleavage produced by the combination. The sensitizing effect essentially disappeared. That asymmetry is the key insight. The combination kills both cell types more effectively than either drug alone, but the mechanism it employs differs between them. In resistant cells, the killing is ROS-dependent. Remove the ROS, and you remove the reversal of resistance. This means the resistant cells carry a specific vulnerability to oxidative stress—one that arises precisely due to the adaptations that made them resistant—and that shikonin paired with paclitaxel is positioned to exploit. There is a metabolic subplot worth understanding here, even if it does not fully resolve. Pyruvate kinase M2, or PKM2, is a rate-limiting enzyme in glycolysis, the metabolic pathway cancer cells rely on heavily for energy. Shikonin had already been identified in previous literature as a PKM2 inhibitor, which made it a possible second mechanism. When the team tested A2780/PTX cells, they found that shikonin alone already suppressed PKM2 expression, and the combination produced an even greater reduction. PKM2 enzymatic activity dropped under combination treatment as well, measured by monitoring absorbance change at three hundred forty nanometres in whole-cell lysate. However, when the team added NAC, the PKM2 suppression vanished completely. Both protein expression and enzymatic activity were restored. This indicates that PKM2 downregulation is downstream of ROS—it is a consequence of the oxidative flood, not a parallel mechanism driving resistance reversal independently. Wang and colleagues are careful about this conclusion. They suggest that PKM2 suppression is likely not crucial to the synergistic effect, and that the cross-talk between shikonin-induced ROS and PKM2 regulation needs further investigation. This finding opens a question rather than closing one. PKM2 may ultimately matter in this story, but not in the way initially hypothesized. If we take a step back, what this study establishes is noteworthy. Wang and colleagues demonstrate that shikonin can resensitize paclitaxel-resistant ovarian cancer cells through a mechanism unrelated to the efflux pump driving that resistance. The pump stays active, but the cells die anyway—because they are being overwhelmed by intracellular oxidative stress that the pump cannot address. This represents a fundamentally different therapeutic logic from the one that has driven decades of P-gp inhibitor development. Instead of trying to outsmart the cell's drug-ejection machinery, one can bypass it entirely by attacking a vulnerability the cell cannot pump away. The safety profile of shikonin deserves a brief mention. The paper notes that a clinical study of a shikonin mixture was reported as safe and effective in patients with advanced lung cancer, which at least offers preliminary support for the idea that this compound class could eventually be tested in humans. However, the authors are appropriately clear that clinical translation remains to be established. This work points toward a rethinking of how we approach drug-resistant cancer. The P-gp pump has been a target because it is visible, measurable, and mechanistically obvious. If resistant cells have distinct oxidative vulnerabilities—vulnerabilities that arise precisely due to the adaptations that made them resistant—then compounds like shikonin that generate ROS through multiple simultaneous mechanisms may be better suited to the problem than single-target inhibitors ever were. The combination of shikonin and paclitaxel, at least in this model, does not overcome resistance by being stronger. It overcomes resistance by being different. This lecture was created by ennepō. Go to https://ennepo.ai to Discover, Create and Follow the latest research in your field. Read when you can. Listen when you want to.